Silk Road Medical (SILK)
(Delayed Data from NSDQ)
$27.50 USD
+0.22 (0.81%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $27.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.50 USD
+0.22 (0.81%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $27.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
What Makes Silk Road Medical (SILK) a New Strong Buy Stock
by Zacks Equity Research
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Silk Road Medical (SILK): Can Its 9.3% Jump Turn into More Strength?
by Zacks Equity Research
Silk Road Medical (SILK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 6.38% and 6.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -17.07% and 5.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -5% and 8.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Silk Road Medical (SILK) Loses 32.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Silk Road Medical (SILK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Silk Road Medical (SILK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -29.03% and -5.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Silk Road Medical (SILK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Silk Road Medical (SILK) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Silk Road Medical (SILK).
Silk Road Medical (SILK) Upgraded to Buy: Here's Why
by Zacks Equity Research
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 16.22% and 4.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Silk Road Medical (SILK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 22.50% and 3.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 25th
by Zacks Equity Research
APG, FLR, ROCK, SILK, and CYD have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2021
Moving Average Crossover Alert: Silk Road Medical (SILK)
by Zacks Equity Research
Silk Road Medical (SILK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Penumbra, Silk Road Medical, EOG Resources, Diamondback Energy and ConocoPhillips highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Silk Road Medical, EOG Resources, Diamondback Energy and ConocoPhillips highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Silk Road Medical (SILK)
by Kevin Cook
Young innovator in stroke prevention has impressive sales growth but EPS just got slashed
Silk Road Medical (SILK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -63.33% and -0.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Silk Road Medical (SILK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.